What Are the Evolocumab Side Effects?

What are the most common side effects of evolocumab?

The most common reported evolocumab side effects include cold-like or upper respiratory symptoms, back pain, muscle pain, and reactions where the medicine is injected. The FDA prescribing information also reports hypersensitivity reactions such as rash, eczema, redness, and hives; swelling (angioedema) has also been reported.

In one 52-week placebo-controlled trial, nasopharyngitis occurred in 10.5% of Repatha-treated patients versus 9.6% on placebo. Upper respiratory infection occurred in 9.3% versus 6.3%, back pain in 6.2% versus 5.6%, injection-site reactions in 5.7% versus 5.0%, and myalgia in 4.0% versus 3.0%. These comparisons help put symptoms in context: a symptom reported during treatment is not automatically caused by the medicine, especially when it also occurs in people receiving placebo.

Cleveland Clinic lists flu-like symptoms, including fever, chills, muscle pain, cough, headache, and fatigue, as possible effects, along with runny or stuffy nose and sore throat. The manufacturer also lists high blood sugar or diabetes among common side effects. Aches or fatigue can be concerning when they persist, but a medication review or personal report alone cannot establish that evolocumab caused them. Record when symptoms began, how they change, and whether they follow an injection, then share that pattern with the prescriber.

How common are muscle or joint pain and injection-site reactions with Repatha?

Muscle-related events and injection-site reactions were uncommon in the major trial data, and their rates were close to placebo. In the FOURIER trial, which followed 27,564 people with cardiovascular disease receiving statin therapy for a median of 2.2 years, injection-site reactions occurred in 2.1% of those given evolocumab and 1.6% given placebo. About 90% of reactions in both groups were classified as mild.

A separate FDA pooled-trial analysis found injection-site reactions in 3.2% of Repatha-treated patients and 3.0% of placebo recipients. Common local reactions included redness, pain, and bruising; only 0.1% of treated patients discontinued because of them. Different trial pools and durations can produce different percentages, so these figures are best read as estimates from distinct study settings, not as a single universal rate.

Muscle symptoms deserve context if you also take a statin. In FOURIER, muscle-related events did not differ significantly between treatment groups. A JAMA Cardiology safety analysis reported such events in 5.0% of evolocumab recipients versus 4.8% of placebo recipients overall; among people on maximal-potency statins, the figures were 5.5% and 5.1%. That evidence does not rule out an individual problem. Tell your prescriber if aches are new, persistent, or worsening, and ask what evaluation is appropriate. For broader statin questions, see Which Statin Has the Least Side Effects?

How long do evolocumab side effects last after an injection?

The available sources do not specify a typical number of hours or days that injection-site reactions, cold-like symptoms, or aches last after a dose. The FOURIER safety analysis says most injection-site reactions were mild, but it does not establish how long each reaction continued. Individual timing can vary, so avoid assuming that a symptom will resolve by a particular day.

Track the practical details instead: the symptom, when it started relative to the injection, whether it is improving or worsening, and whether it returns after later doses. For bothersome symptoms that do not go away, the Repatha patient information says to tell your doctor; Cleveland Clinic likewise advises reporting symptoms that persist or worsen. This gives the prescriber useful information without treating timing alone as proof of cause.

Use urgency to decide what to do next. Trouble breathing or swallowing, or swelling of the face, lips, tongue, or throat, calls for emergency help. For symptoms that are uncomfortable but not urgent, contact your prescriber or care team for individualized guidance. Cleveland Clinic advises patients to keep taking the medicine unless their care team tells them to stop; the FDA label directs discontinuation and appropriate care if signs or symptoms of serious hypersensitivity occur.